Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

Hengeveld M, Suciu S, Karrasch M, Specchia G, Marie JP, Muus P, Petti MC, Rotoli B, Amadori S, Fioritoni G, Leoni P, Morra E, Thaler J, Resegotti L, Fazi P, Vignetti M, Mandelli F, Zittoun R, de Witte T.

Ann Hematol. 2012 Jun;91(6):825-35. doi: 10.1007/s00277-012-1436-z. Epub 2012 Mar 31.

2.

Risk of second cancer in patients with hairy cell leukemia: long-term follow-up.

Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A, Annino L, Chisesi T, Pagnucco G, Invernizzi R, Spriano M, Resegotti L, Bendandi M, Damasio EE; Italian Cooperative Group for the Study of Hairy Cell Leukemia.

J Clin Oncol. 2002 Feb 1;20(3):638-46.

PMID:
11821443
3.

Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.

Guglielmi C, Martelli M, Federico M, Zinzani PL, Vitolo U, Bellesi G, Santini G, Tarella C, Zallio F, Pregno P, Di Renzo N, Resegotti L; Italian Intergroup for Lymphomas.

Haematologica. 2001 Sep;86(9):941-50.

4.

Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions.

Migliazza A, Cayanis E, Bosch-Albareda F, Komatsu H, Martinotti S, Toniato E, Kalachikov S, Bonaldo MF, Jelene P, Ye X, Rzhetsky A, Qu X, Chien M, Inghirami G, Gaidano G, Vitolo U, Saglio G, Resegotti L, Zhang P, Soares MB, Russo J, Fischer SG, Edelman IS, Efstratiadis A, Dalla-Favera R.

Curr Top Microbiol Immunol. 2000;252:275-84. Review. No abstract available.

PMID:
11125485
5.

Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L.

Blood. 2000 Feb 1;95(3):783-9.

PMID:
10648386
6.

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

Keating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B, Resegotti L, Ferrini PR, Caronia F, Dardenne M, Solbu G, Petti MC, Vegna ML, Mandelli F, Zittoun RA.

Br J Haematol. 1998 Sep;102(5):1344-53.

PMID:
9753069
7.

The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy.

Dammacco F, Silvestris F, Castoldi GL, Grassi B, Bernasconi C, Nadali G, Perona G, De Laurenzi A, Torelli U, Ascari E, Rossi Ferrini PL, Caligaris-Cappio F, Pileri A, Resegotti L.

Int J Clin Lab Res. 1998;28(2):127-34.

PMID:
9689556
8.

Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients.

Vitolo U, Gaidano G, Botto B, Volpe G, Audisio E, Bertini M, Calvi R, Freilone R, Novero D, Orsucci L, Pastore C, Capello D, Parvis G, Sacco C, Zagonel V, Carbone A, Mazza U, Palestro G, Saglio G, Resegotti L.

Ann Oncol. 1998 Jan;9(1):55-61.

PMID:
9541684
9.

Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history.

Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, Orsucci L, Vitolo U, Palestro G, Resegotti L.

Haematologica. 1998 Apr;83(4):312-6.

10.

Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.

Damasio EE, Resegotti L, Masoudi B, Bruni R, Cerri R, Isaza A, Clavio M, Risso M, Rossi E, Spriano M, Truini M.

Recenti Prog Med. 1998 Feb;89(2):68-73.

PMID:
9558908
11.

Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial.

Zittoun R, Suciu S, Watson M, Solbu G, Muus P, Mandelli F, Stryckmans P, Peetermans M, Thaler J, Resegotti L, Dardenne M, Willemze R.

Bone Marrow Transplant. 1997 Aug;20(4):307-15.

12.

Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia.

Gaidano G, Pastore C, Santini V, Nomdedeu J, Gamberi B, Capello D, Vischia F, Resegotti L, Mazza U, Ferrini PR, Lo Coco F, Saglio G.

Genes Chromosomes Cancer. 1997 Aug;19(4):250-5.

PMID:
9258660
13.

Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia.

Kalachikov S, Migliazza A, Cayanis E, Fracchiolla NS, Bonaldo MF, Lawton L, Jelenc P, Ye X, Qu X, Chien M, Hauptschein R, Gaidano G, Vitolo U, Saglio G, Resegotti L, Brodjansky V, Yankovsky N, Zhang P, Soares MB, Russo J, Edelman IS, Efstratiadis A, Dalla-Favera R, Fischer SG.

Genomics. 1997 Jun 15;42(3):369-77.

PMID:
9205107
14.

Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.

Giona F, Annino L, Rondelli R, Arcese W, Meloni G, Testi AM, Moleti ML, Amadori S, Resegotti L, Tabilio A, Ladogana S, Fioritoni G, Camera A, Liso V, Leoni P, Mandelli F.

Br J Haematol. 1997 Jun;97(4):896-903.

PMID:
9217194
15.

Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin).

Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, Meneghini V, Orlandi E, Orsucci L, Pizzuti M, Rota Scalabrini D, Salvi F, Todeschini G, Vitolo U, Resegotti L.

Haematologica. 1997 May-Jun;82(3):309-13.

16.
17.

Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.

Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L.

J Clin Oncol. 1997 Feb;15(2):491-8.

PMID:
9053470
18.

Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma.

Freilone R, Botto B, Vitolo U, Bertini M, Audisio E, Calvi R, Cucchi M, De Crescenzo A, Gallamini A, Ghio R, Griso L, Levis A, Massara G, Orsucci L, Ricardi U, Rota Scalabrini D, Salvi F, Secondo V, Resegotti L.

Ann Oncol. 1996 Nov;7(9):919-24.

PMID:
9006742
19.

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahé B, Couteaux ME, Resegotti L, Voglova V, Foussard C, Pegourié B, Michaux JL, Deconinck E, Stoppa AM, Mufti G, Oscier D, Fenaux P.

Blood. 1996 Oct 1;88(7):2480-7.

PMID:
8839839
20.

Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients.

Levis A, Depaoli L, Bertini M, Botto B, Ciravegna G, Freilone R, Gallamini A, Gavarotti P, Ricardi U, Rota Scalabrini D, Salomone A, Salvi F, Vitolo U, Pileri A, Sannazzari GL, Resegotti L.

Haematologica. 1996 Sep-Oct;81(5):450-6.

21.

The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.

Bertini M, Freilone R, Vitolo U, Botto B, Ciotti R, Cinieri S, Di Nota A, Di Vito F, Levis A, Orsucci L, Pini M, Rota-Scalabrini D, Todeschini G, Resegotti L.

Leuk Lymphoma. 1996 Aug;22(5-6):483-93.

PMID:
8882962
22.

Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.

Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L, Broccia G, Thaler J, Labar B, Damasio E, Bizzi B, Rotoli B, Vekhoff A, Muus P, Petti MC, Dardenne M, Solbu G, Vegna ML, Zittoun RA.

Bone Marrow Transplant. 1996 Jun;17(6):993-1001.

PMID:
8807105
23.

Molecular heterogeneity of B-lineage diffuse large cell lymphoma.

Volpe G, Vitolo U, Carbone A, Pastore C, Bertini M, Botto B, Audisio E, Freilone R, Novero D, Cappia S, De Giuli P, Mazza U, Resegotti L, Palestro G, Saglio G, Gaidano G.

Genes Chromosomes Cancer. 1996 May;16(1):21-30.

PMID:
9162193
24.

Correlation between argyrophilic nucleolar organizer region counts and labelling index in multiple myeloma.

Marmont F, Pich A, Chiusa L, Locatelli F, Falda M, Boccadoro M, Resegotti L.

Eur J Haematol. 1996 Jan-Feb;56(1-2):39-44.

PMID:
8599992
25.

Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission.

Guerrasio A, Rosso C, Martinelli G, Lo Coco F, Pampinella M, Santoro A, Lanza C, Allione B, Resegotti L, Saglio G.

Br J Haematol. 1995 Jun;90(2):364-8.

PMID:
7794758
26.

Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.

Bezwoda W, Rastogi RB, Erazo Valla A, Diaz-Maqueo JC, Pavlovsky S, Morioka H, Resegotti L, Rueckle H, Somoza N, Moreno-Nogueira JA, et al.

Eur J Cancer. 1995 Jun;31A(6):903-11.

PMID:
7646919
28.

Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL).

Capnist G, Federico M, Chisesi T, Resegotti L, Lamparelli T, Fabris P, Rossi G, Invernizzi R, Guarnaccia C, Leoni P, et al.

Leuk Lymphoma. 1994 Aug;14(5-6):457-64.

PMID:
7812205
29.

Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia.

Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, Dini E, Resegotti L, Damasio EE, Silingardi V.

Leuk Lymphoma. 1994 Apr;13(3-4):307-16. Review.

PMID:
7519510
30.

B-cell chronic lymphocytic leukaemia stage 0. An immunophenotypic study of 66 cases and comparison with B small cell lymphomas.

Stramignoni A, Valente G, Geuna M, Stramignoni D, Novero D, Ragona R, Resegotti L, Palestro G.

Eur J Haematol. 1994 Mar;52(3):145-51.

PMID:
8168593
31.

Probability of cure in elderly Hodgkin's disease patients.

Levis A, Depaoli L, Urgesi A, Bertini M, Orsucci L, Vitolo U, Buchi G, Gallamini A, Gavarotti P, Novarino A, Rota Scalabrini D, Mazza U, Pileri A, Sannazzari GL, Resegotti L.

Haematologica. 1994 Jan-Feb;79(1):46-54.

32.

EORTC-GIMEMA AML8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML).

Zittoun R, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Ferrini PR, Visani G, Caronia F, Stryckmans P, et al.

Leuk Lymphoma. 1994;13 Suppl 1:101. No abstract available.

PMID:
8075572
33.

Prognostic significance of CD34 expression and CD33/CD13 ratio in acute myeloid leukemia.

Levis A, Depaoli L, Isabella N, Resegotti L.

Haematologica. 1993 Nov-Dec;78(6):420. No abstract available.

PMID:
8175042
34.

Quantitative expression of HLA class I molecules in acute non-lymphoblastic leukaemia cells.

D'Alfonso S, Savoia P, Pitti G, Peruccio D, Pozzi C, Crepaldi T, Falda M, Ficara F, Resegotti L, Momigliano Richiardi P.

Eur J Immunogenet. 1993 Jun;20(3):165-73.

PMID:
8338814
35.

The therapy of hematological malignancies in the elderly.

Resegotti L.

Haematologica. 1993 May-Jun;78(3):141-4. No abstract available.

PMID:
8375743
36.

Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.

Depaoli L, Levis A, Isabella N, Ficara F, Priotto C, Lista P, Foà R, Resegotti L.

Haematologica. 1993 Mar-Apr;78(2):118-22.

PMID:
8349187
37.

Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.

Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, et al.

Leukemia. 1993 Feb;7(2):196-9.

PMID:
8426473
38.

The nature and natural history of myelodysplasia.

Resegotti L.

Haematologia (Budap). 1993;25(3):191-204. Review. No abstract available.

PMID:
8119632
39.

Argyrophilic nucleolar organizer region counts and prognosis in multiple myeloma.

Pich A, Marmont F, Chiusa L, Cappello N, Resegotti L, Navone R.

Br J Haematol. 1992 Dec;82(4):681-8.

PMID:
1482655
40.

Hairy cell leukemia: the Italian Cooperative Group experience.

Federico M, Frassoldati A, Lamparelli T, Dini E, Resegotti L, Damasio EE.

Leukemia. 1992 Nov;6 Suppl 4:147-8. No abstract available.

PMID:
1279328
41.

Evaluation of bone marrow cellularity by magnetic resonance imaging in patients with myelodysplastic syndrome.

Depaoli L, Davini O, Foggetti MD, Ficara F, Priotto C, Cirillo R, Resegotti L.

Eur J Haematol. 1992 Aug;49(2):105-7.

PMID:
1397236
42.

Hairy cell leukemia: splenectomy after alpha-interferon therapy.

Damasio EE, Resegotti L, Capnist G, Federico M, Foá R, Francia P, Lamparelli T.

Blood. 1992 Mar 1;79(5):1381. No abstract available.

PMID:
1599545
43.

[Magnetic resonance in the study of residual mediastinal masses after therapy of lymphoma].

Davini O, Levis A, Garabello D, Foggetti MD, Depaoli L, Cirillo R, De Lucchi R, Orsucci L, Resegotti L.

Radiol Med. 1992 Mar;83(3):230-6. Italian.

PMID:
1579671
44.

Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.

Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC, et al.

Leukemia. 1992;6 Suppl 2:76-7. No abstract available.

PMID:
1578949
45.
46.

Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study.

Bernasconi C, Lazzarino M, Morra E, Alessandrino EP, Pagnucco G, Resegotti L, Locatelli F, Ficarra F, Bacigalupo A, Carella AM, et al.

Leukemia. 1992;6 Suppl 2:204-8.

PMID:
1578935
47.

Allogeneic or autologous bone marrow transplantation for intensification of salvage therapy in patients with high-risk advanced acute lymphoblastic leukemia. The AIEOP/GIMEMA Groups.

Arcese W, Amadori S, Meloni G, Giona F, Vegna ML, Testi AM, Annino L, Carotenuto M, Resegotti L, Madon E, et al.

Semin Hematol. 1991 Jul;28(3 Suppl 4):116-21. No abstract available.

PMID:
1780745
48.
49.

Prognostic significance of serum albumin in chronic lymphocytic leukemia.

Levis A, Ficara F, Marmont F, De Crescenzo A, Resegotti L.

Haematologica. 1991 Mar-Apr;76(2):113-9.

PMID:
1937168
50.

Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.

Vitolo U, Orsucci L, Bertini M, Cavallero G, Gallamini A, Ghio R, Levis A, Rota-Scalabrini D, Resegotti L.

Haematologica. 1991 Jan-Feb;76(1):43-6.

PMID:
2055560

Supplemental Content

Loading ...
Support Center